3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Head and Neck Neoplasms
3
Nasopharyngeal Carcinoma
2
Lymphoma, Non-Hodgkin
2
Leukemia
2
Hematologic Neoplasms
2
Squamous Cell Carcinoma of Head and Neck
1
Plasmacytoma
1
Neoplasms
1
Lymphoma, T-Cell, Peripheral
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Lymphoma
1
Lung Neoplasms
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hypopharyngeal Neoplasms
1
Hodgkin Disease
1
Esophageal Squamous Cell Carcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Hepatocellular
1
Advanced Gastric Cancer
1
Adenocarcinoma of Lung
1
Interventions
Cisplatin
115
Radiotherapy
83
Paclitaxel
77
Fluorouracil
61
Carboplatin
41
Drug Therapy
34
pembrolizumab
33
Irinotecan
33
tislelizumab
27
Docetaxel
26
toripalimab
23
Oxaliplatin
23
Neoadjuvant Therapy
23
Radiation
20
sintilimab
19
camrelizumab
19
130-nm albumin-bound paclitaxel
18
Esophagectomy
17
Capecitabine
17
Surgical Procedures, Operative
15
Leucovorin
15
Nivolumab
14
Cetuximab
14
TP protocol
12
S 1 (combination)
12
Radiotherapy, Intensity-Modulated
12
Albumin-Bound Paclitaxel
12
nimotuzumab
11
apatinib
10
anlotinib
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Esophageal Squamous Cell Carcinoma
×
CF regimen
×
Clear all
NCT04550260
2026-05-13
KUNLUN
AstraZeneca
Phase 3
Active not recruiting
640 enrolled